Minor cannabinoids & nootropics (regulatory positioning)

Minor cannabinoid and nootropic positioning sits at the contested edges of the supplement framework. Minor cannabinoids — CBG, CBN, CBC, CBDV, CBDA, THCV — derived from compliant hemp (delta-9 THC <0.3% dry weight) fall within the 2018 Farm Bill scope subject to the FDA exclusionary clause unresolved status (FDA position: cannabinoids are not lawful dietary supplement ingredients because they are subjects of active drug investigation). State-level legality varies. Semi-synthetic cannabinoids — delta-8 THC, delta-10 THC, HHC, THCP, THCO — produced through chemical isomerisation carry significantly higher risk: DEA position excludes synthetic isomers from Farm Bill hemp scope, over 20 states have explicit restrictions, THCO has been classified Schedule I, FDA Warning Letters target manufacturers for adulteration and marketing to children. Nootropic positioning operates in three tiers — Tier 1 GRAS botanicals (Bacopa, Rhodiola, ashwagandha, lion's mane) generally lawful with structure/function claims, Tier 2 well-substantiated nutrients (L-theanine, citicoline, alpha-GPC, phosphatidylserine, caffeine) lawful with established evidence, Tier 3 racetams (piracetam, aniracetam, oxiracetam, phenylpiracetam, noopept) categorically not lawful US supplements (not dietary ingredients, not FDA-approved drugs, prescription pharmaceuticals in EU). Adaptogen claims (Rhodiola, ashwagandha, eleuthero, Schisandra) under active FTC scrutiny requiring competent and reliable scientific evidence; EFSA Article 13 absent; per-market claim discipline mandatory.